Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.
See Undervalued Stocks
Novartis upgrades sales forecast
Author
Published Nov 21, 2024 05:37AM ET
© Reuters.
Investing.com -- Novartis (SIX:NOVN) has raised its growth guidance, indicating optimism about its mid-term performance, even as questions about longer-term sustainability persist.
The pharmaceutical company has upgraded its 2023-2028 CAGR sales guidance to 6%, surpassing the previous target of 5%, and issued a new 2024-2029 guidance at 5%, which is higher than the consensus estimate of 3%.
“In general, we see the updates as in-line with both our own and investor expectations,” said analysts at Barclays (LON:BARC) in a note.
These adjustments imply that Novartis expects its 2028 and 2029 sales to exceed consensus by approximately 7% and 11%, respectively.
Analysts at BofA Securities noted that while these upgrades align more closely with their optimistic projections, market skepticism remains about the company’s ability to sustain growth post-2029.
Key drivers behind Novartis' updated outlook include strengthened expectations for several products. Sales forecasts for Kisqali and Kesimpta, both estimated to surpass $8 billion and $6 billion, respectively.
Similarly, Pluvicto and Leqvio are projected to report over $5 billion and $4 billion in peak sales, with major contributions expected from the broader pipeline.
Despite the optimistic mid-term outlook, challenges loom on the horizon. Patent expiration risks for Kisqali (expected by 2031) and Kesimpta (2030-2032) are anticipated to pose headwinds.
Additionally, questions about margin stability beyond 2028 remain unanswered, as the company continues to target a core operating income margin above 40% through 2027.
Analysts flagged this as a critical point of scrutiny, particularly as competition intensifies and more cost-effective biosimilar alternatives enter the market.
Novartis' guidance revisions are underpinned by its capital allocation strategy, which includes organic investments, dividends, share buybacks, and bolt-on acquisitions.
However, BofA Securities analysts maintain a neutral stance, citing limited near-term catalysts to drive earnings outperformance.
They flagged potential risks such as Kisqali's ongoing patent litigation and a lack of major late-stage pipeline breakthroughs as factors constraining the company's valuation.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.